1. AF.50 SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY. (September 2021) Authors: Mazza, S.; Piazza O Sed, N.; Conforti, F.S.; Fascì, A.; Casini, V.; Ricci, C.; Munari, F.; Pirola, L.; Invernizzi, P.; Girelli, C.; Lupinacci, G.; Pastorelli, L.; Cavallaro, F.; Ferraris, L.; Colucci, A.; Amato, A.; Tontini, G.E.; Vecchi, M.; Fiorino, G.; Caprioli, F. Journal: Digestive and liver disease Issue: Volume 53(2021)Supplement 3 Page Start: S159 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗